"Sorafenib dose escalation in treatment‐naïve patients with metastatic renal cell carcinoma: a non‐randomised, open‐label, Phase 2b study"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Sorafenib dose escalation in treatment‐naïve patients with metastatic renal cell carcinoma: a non‐randomised, open‐label, Phase 2b study

To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma (mRCC). Click to show full abstract

To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma (mRCC).

Keywords: renal cell; dose escalation; cell carcinoma; sorafenib dose; metastatic renal

Journal Title: BJU International
Year Published: 2017

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended